A biosimilar is a biologic that is highly similar to the reference product with no clinically meaningful differences in terms of the safety, purity, and potency. Pfizer is helping change the US biologic landscape by providing patients with more treatment options through the largest portfolio of potentially cost-saving biosimilars. Pfizer has more than 12 years of experience producing biosimilars globally & leverages more than 30 years of state-of-the-art manufacturing experience in biologics. To learn more about Pfizer Biosimilars treatment options, click here.